Course of the SARS-CoV-2 (COVID-19) infection and tolerability of the SARS-CoV-2 vaccinations in patients with epilepsies in an epilepsy outpatient clinic

• Conditions: G40.2; G40.3; Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures; Generalized idiopathic epilepsy and epileptic syndromes

• Registration Number: DRKS00028046
• Lead Sponsor: Epilepsiezentrum Kork

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-02-04
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 1200

Inclusion Criteria

Age> / = 18 years in outpatient treatment in our epilepsy center between December 2021 and December 2022
- Patients with confirmed epilepsies
- Either confirmed SARS-CoV-2 infection or vaccination against SARS-CoV-2

Exclusion Criteria

- Patients without a confirmed diagnosis of epilepsy and / or with psychogenic, non-epiletic seizures
- A declaration of consent cannot be obtained from the patient or their legal representative

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Frequency of seizures during and after the SARS-CoV-2 infection and in connection with the SARS-CoV-2 vaccination

Secondary Outcome Measures

Name	Time	Method
Additional safety endpoints such as aggravation of the seizure situation or central nervous system side effects in relation to the time of the SARS-CoV-2 infection and vaccination